A Phase II, Multicenter, Open-Label Clinical Study to Evaluate the Safety, Tolerability and Efficacy of SHR-1826 for Injection in Patients With NSCLC
Latest Information Update: 24 Mar 2025
At a glance
- Drugs Adebrelimab (Primary) ; SHR 1826 (Primary) ; SHR 8068 (Primary) ; Bevacizumab
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Suzhou Suncadia Biopharmaceuticals
Most Recent Events
- 19 Mar 2025 Status changed from not yet recruiting to recruiting.
- 04 Mar 2025 New trial record